Another week and another big pharma has enlisted the services of a generative AI company to accelerate drug discovery. In the latest deal, Bristol Myers Squibb (BMS) has entered a collaboration with US deep tech company VantAI.
The partnership will focus on using VantAI鈥檚 generative AI platform (GenAI) to design and develop molecular glues 鈥� a type of small molecule that induces or stabilises interactions between two proteins that would not normally go together.
If certain milestones are met, VantAI could be in line to receive up to $674m from BMS. Tiered royalties are also included in the deal, as per a 13 February press release.
BMS and VantAI did not disclose the therapeutic areas initially being targeted and the big pharma has the option to further expand this collaboration into additional programmes.
VantAI鈥檚 technology uses geometric deep learning to mimic interfaces that have been naturally occurring for millions of years. The company produces insights from these evolved interfaces to help in the candidate design process. The AI company calls this approach 鈥減rotein-contact-first鈥�, saying it yields 鈥済lue-like solutions鈥� that could exhibit better potency, selectivity, and molecule size.
VantAI CEO Dr Zachary Carpenter said: 鈥淢olecular glues have proven extremely difficult to find, but hold great promise as a treatment modality across a vast array of diseases.鈥�
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBMS is the second big name to tap VantAI鈥檚 platform. In 2022, Janssen 色界吧 Companies of Johnson and Johnson (J&J) entered a multi-year collaboration with the AI company. The partnership was initially focused on two degrader programmes, as well as an E3 ligase project. J&J did not disclose the financial terms of the deal.
This will not be BMS鈥� first initiative into molecular glues. In the same year as J&J and VantAI鈥檚 partnership, BMS signed a $550m deal with biotech SyntheX to target small-molecule degraders, including certain E3 ligases.
GenAI is a buzzword in today鈥檚 healthcare industry, and pharma companies have been active in harnessing its potential, especially for drug discovery. MSD, Genentech, and Eli Lilly have partnered with Amazon, NVIDIA, and Genesis, respectively, for such collaborations.
The startup space for GenAI is burgeoning too. Deep learning biotech startup Evozyne, which uses AI to simulate millions of years of evolution in proteins to identify targets, raised $81m in a Series B round in September 2023. Eli-Lilly-partnered Genesis raised $200m in Series B financing in August 2023 while Aqemia, which partnered with Sanofi in a $140m deal, has a Series A funding round total of $65m.
